Meeting
2023 ASCO Annual Meeting
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
Authors
Jeffrey Lee Jensen
University of North Carolina Hospital, Chapel Hill, NC
Jeffrey Lee Jensen , Olivia Bobek , Irenaeus Chi-Chung Chan , David W. Hillman , Glenn Heller , Todd E. Druley , Michael J. Morris , Matthew I. Milowsky , Himisha Beltran , KELLY L. BOLTON , Catherine Callaghan Coombs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5021)
DOI
10.1200/JCO.2023.41.16_suppl.5021
Abstract #
5021
Poster Bd #
115
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.
First Author: Catherine Handy Marshall
Poster
2022 ASCO Annual Meeting
Impact of clonal hematopoiesis on tumor control following radiation therapy.
First Author: Jacqueline Tao
Poster
2020 ASCO Virtual Scientific Program
Type of prior genotoxic insult determines the genomic characteristics of therapy-related acute myeloid leukemia.
First Author: Michael Ozga
Poster
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
First Author: Catherine Callaghan Coombs